See more : Emperor Entertainment Hotel Limited (0296.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Veradigm Inc. (MDRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Veradigm Inc., a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
- Kantone Holdings Limited (1059.HK) Income Statement Analysis – Financial Results
- Chinawe.com Inc. (CHWE) Income Statement Analysis – Financial Results
- Petrofac Limited (PFC.L) Income Statement Analysis – Financial Results
- Xiaomi Corporation (3CP.F) Income Statement Analysis – Financial Results
- Zhejiang Liming Intelligent Manufacturing Co.,Ltd. (603048.SS) Income Statement Analysis – Financial Results
Veradigm Inc. (MDRX)
About Veradigm Inc.
Veradigm Inc., a healthcare technology company, provides information technology solutions to healthcare providers, payers, and biopharma markets in the United States and internationally. The company offers solutions to healthcare providers, comprising Practice Management software, AI Patient Scheduling Software, and Electronic Statements and Payments; revenue cycle management solutions, including Revenue Cycle Services and revenue cycle management clearinghouse; electronic health records solutions, which include ePrescribe with EPCS, EHR software, Veradigm HER, and Practice Fusion HER; and Patient Engagement Platform. It also provides solutions to network partners, which comprise API connectivity solutions, such as Veradigm Connect, Veradigm App Expo, and Diagnostic Ordering and Resulting Network; Channel Partner Program; and Veradigm ePrescribe Enterprise. In addition, the company offers solutions to health plans and payers, comprising risk adjustment solutions, such as Health Equity Analytics, Risk Adjustment Analytics, Risk Mitigator, Comprehensive Submissions, and Utilization Analytics; quality management solutions, which include quality analytics and risk adjustment and quality management; data exchange+coding solutions, including eChart Courier, eChart Coder, and eChart Integration and Analytics; provider engagement and Veradigm Payer Insights; and Veradigm Payerpath solutions. Further, it provides solutions to biophama, including real world data solutions, such as real world and health data sets and cardiology and metabolic registries; real world evidence and Real World Evidence Analytics Platform; therapy focused solutions, such as cardiovascular, central nervous system, metabolic, and immunology data; and Digital Health Media solutions. The company was formerly known as Allscripts Healthcare Solutions, Inc. and changed its name to Veradigm Inc. in January 2023. Veradigm Inc. was founded in 1986 and is headquartered in Chicago, Illinois.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 1.50B | 1.50B | 1.77B | 1.75B | 1.81B | 1.55B | 1.39B | 1.38B | 1.37B | 1.45B | 1.45B | 704.50M | 704.50M | 383.80M | 281.91M | 227.97M | 120.56M | 100.77M | 85.84M | 78.80M | 70.75M | 62.69M | 27.60M | 23.70M |
| Cost of Revenue | 0.00 | 883.40M | 937.01M | 1.06B | 1.03B | 1.02B | 878.90M | 805.80M | 831.90M | 838.60M | 839.80M | 778.50M | 315.66M | 315.70M | 176.90M | 141.50M | 112.03M | 65.69M | 58.12M | 55.17M | 58.93M | 66.12M | 39.40M | 20.90M | 16.20M |
| Gross Profit | 0.00 | 619.60M | 565.70M | 713.60M | 724.60M | 782.10M | 671.00M | 580.60M | 546.00M | 534.50M | 606.50M | 670.60M | 388.84M | 388.80M | 206.90M | 140.41M | 115.94M | 54.88M | 42.65M | 30.67M | 19.87M | 4.63M | 23.29M | 6.70M | 7.50M |
| Gross Profit Ratio | 0.00% | 41.22% | 37.65% | 40.28% | 41.41% | 43.30% | 43.29% | 41.88% | 39.63% | 38.93% | 41.93% | 46.28% | 55.19% | 55.19% | 53.91% | 49.81% | 50.86% | 45.52% | 42.32% | 35.73% | 25.22% | 6.55% | 37.15% | 24.28% | 31.65% |
| Research & Development | 0.00 | 193.70M | 206.06M | 254.50M | 268.40M | 220.20M | 187.90M | 184.80M | 192.80M | 199.80M | 162.10M | 104.10M | 49.21M | 49.20M | 37.80M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 117.60M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 0.00 | 313.80M | 389.94M | 419.80M | 451.00M | 486.30M | 392.80M | 339.20M | 358.70M | 419.60M | 384.40M | 389.60M | 225.00M | 225.00M | 117.60M | 101.67M | 85.80M | 43.91M | 37.65M | 36.06M | 36.41M | 57.91M | 42.73M | 20.70M | 13.10M |
| Other Expenses | 0.00 | 23.10M | 25.60M | 27.20M | 26.60M | 33.70M | 1.09M | 2.18M | 400.00K | 7.30M | 0.00 | 0.00 | 0.00 | 0.00 | 11.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 0.00 | 530.60M | 621.61M | 701.50M | 746.00M | 740.20M | 606.50M | 547.20M | 582.80M | 650.60M | 582.10M | 531.00M | 274.20M | 284.20M | 166.60M | 112.30M | 96.07M | 45.65M | 39.41M | 37.01M | 36.95M | 467.99M | 71.37M | 23.20M | 14.60M |
| Cost & Expenses | 0.00 | 1.41B | 1.56B | 1.76B | 1.77B | 1.76B | 1.49B | 1.35B | 1.41B | 1.49B | 1.42B | 1.31B | 589.86M | 599.90M | 343.50M | 253.80M | 208.10M | 111.34M | 97.53M | 92.18M | 95.88M | 534.11M | 110.76M | 44.10M | 30.80M |
| Interest Income | 0.00 | 1.10M | 34.10K | 43.17K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 14.61M | 1.70M | 0.00 | 900.00K | 156.00K | 3.96M | 3.31M | 4.13M | 1.68M | 1.38M | 2.41M | 5.06M | 7.71M | 0.00 | 0.00 |
| Interest Expense | 0.00 | 13.20M | 34.10M | 43.20M | 50.90M | 87.50M | 63.00M | 30.00M | 29.30M | 28.00M | 30.80M | 20.80M | -1.99M | 2.00M | 1.69M | 3.72M | 3.71M | 3.52M | 1.72M | 0.00 | 155.00K | 283.00K | 0.00 | 0.00 | 600.00K |
| Depreciation & Amortization | 228.49K | 192.78M | 236.59M | 250.61M | 192.35M | 157.33M | 172.39M | 161.00M | 174.30M | 178.80M | 150.20M | 37.30M | 0.00 | 10.00M | 16.20M | 21.47M | 16.46M | 6.53M | 4.97M | 4.93M | 5.56M | 68.01M | 28.63M | 2.50M | 1.50M |
| EBITDA | 0.00 | 279.81M | 77.06M | -24.46M | 173.07M | 41.92M | 240.38M | 199.95M | 135.44M | 54.62M | 143.90M | 178.60M | 104.58M | 115.50M | 68.88M | 28.11M | 19.87M | 9.22M | 3.24M | -1.41M | -11.52M | -395.34M | -26.15M | -14.00M | -5.60M |
| EBITDA Ratio | 0.00% | 24.15% | 11.60% | 5.84% | 9.78% | 14.49% | 14.87% | 14.03% | 10.01% | 5.10% | 12.07% | 12.32% | 14.84% | 16.39% | 14.62% | 16.74% | 16.00% | 13.17% | 8.24% | -1.61% | -14.11% | -44.47% | -9.11% | -50.72% | -23.63% |
| Operating Income | 0.00 | 186.80M | -38.66M | -126.10M | -21.10M | 41.90M | 59.80M | 31.90M | -39.20M | -127.60M | 13.30M | 139.60M | 104.58M | 104.60M | 39.90M | 28.11M | 19.87M | 9.22M | 3.24M | -6.34M | -17.68M | -472.79M | -72.63M | -16.50M | -7.10M |
| Operating Income Ratio | 0.00% | 12.43% | -2.57% | -7.12% | -1.21% | 2.32% | 3.86% | 2.30% | -2.84% | -9.29% | 0.92% | 9.63% | 14.84% | 14.85% | 10.40% | 9.97% | 8.72% | 7.65% | 3.22% | -7.38% | -22.44% | -668.22% | -115.86% | -59.78% | -29.96% |
| Total Other Income/Expenses | 0.00 | 72.86M | -93.40M | -155.65M | 106.19M | -231.94M | -36.15M | -31.31M | -28.93M | -20.75M | -30.73M | -19.07M | -1.05M | -1.05M | -5.73M | 2.64M | -549.00K | 487.00K | -135.00K | 1.36M | 2.45M | 5.31M | 6.71M | 0.00 | 0.00 |
| Income Before Tax | 0.00 | 161.80M | -149.31M | -206.50M | 13.10M | -209.60M | -14.80M | 600.00K | -68.10M | -148.30M | -17.50M | 120.50M | 103.54M | 103.50M | 40.20M | 30.75M | 19.32M | 9.71M | 3.11M | -4.98M | -15.23M | -467.48M | -86.36M | 0.00 | 0.00 |
| Income Before Tax Ratio | 0.00% | 10.77% | -9.94% | -11.66% | 0.75% | -11.60% | -0.95% | 0.04% | -4.94% | -10.80% | -1.21% | 8.32% | 14.70% | 14.69% | 10.47% | 10.91% | 8.47% | 8.05% | 3.08% | -5.80% | -19.33% | -660.70% | -137.76% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 27.90M | -16.69M | -23.90M | 400.00K | -50.70M | -17.80M | 2.60M | -1.60M | -44.30M | -16.30M | 45.00M | -40.67M | 40.60M | 14.80M | 10.19M | 7.42M | -487.00K | 135.00K | -1.36M | -1.85M | -48.54M | 9.29M | -5.20M | 400.00K |
| Net Income | 0.00 | 134.44M | -132.62M | -182.60M | 363.70M | -196.50M | -25.70M | -2.20M | -66.50M | -104.00M | -1.20M | 75.50M | 144.20M | 62.90M | 25.40M | 20.56M | 11.90M | 9.71M | 3.11M | -4.98M | -15.23M | -418.93M | -57.37M | -11.30M | -7.50M |
| Net Income Ratio | 0.00% | 8.94% | -8.83% | -10.31% | 20.78% | -10.88% | -1.66% | -0.16% | -4.83% | -7.57% | -0.08% | 5.21% | 20.47% | 8.93% | 6.62% | 7.29% | 5.22% | 8.05% | 3.08% | -5.80% | -19.33% | -592.10% | -91.51% | -40.94% | -31.65% |
| EPS | 0.00 | 1.03 | -0.83 | -1.10 | 2.07 | -1.09 | -0.14 | -0.01 | -0.37 | -0.59 | -0.01 | 0.40 | 0.99 | 0.42 | 0.31 | 0.37 | 0.23 | 0.24 | 0.08 | -0.13 | -0.40 | -11.07 | -2.06 | -0.77 | -1.63 |
| EPS Diluted | 0.00 | 0.96 | -0.83 | -1.10 | 2.04 | -1.09 | -0.14 | -0.01 | -0.37 | -0.59 | -0.01 | 0.40 | 0.99 | 0.42 | 0.31 | 0.35 | 0.22 | 0.23 | 0.07 | -0.13 | -0.40 | -11.07 | -2.06 | -0.66 | -1.63 |
| Weighted Avg Shares Out | 128.90M | 130.14M | 159.28M | 166.31M | 176.00M | 180.80M | 186.19M | 185.08M | 179.80M | 177.00M | 178.70M | 189.30M | 145.10M | 145.10M | 82.90M | 55.71M | 51.06M | 40.05M | 38.98M | 38.62M | 38.34M | 37.84M | 27.90M | 14.72M | 4.60M |
| Weighted Avg Shares Out (Dil) | 128.90M | 138.66M | 159.28M | 166.31M | 178.50M | 180.80M | 186.20M | 185.10M | 179.80M | 177.00M | 178.70M | 191.00M | 145.10M | 148.40M | 82.90M | 64.67M | 53.37M | 43.07M | 41.59M | 38.62M | 38.34M | 37.84M | 27.90M | 17.14M | 4.60M |
Veradigm Launches an Ambient Scribe Advancement to Ease the Healthcare Administrative Burden
Veradigm Advancing Point of Care Engagement Through Payer-Provider Collaboration
Veradigm And The 2025 M&A Boom
Veradigm Advances Deeper Clinical Insights Through NLP-Enhanced EHR Data
Veradigm Ranked Top Vendor by KLAS
Veradigm Named as the Top Vendor for End-to-End Revenue Cycle Management Solutions
Healthcare Information Exchange Industry Report 2024 - Global Market Size, Share, Trends, and Forecasts to 2029 Featuring Epic Systems, Oracle, InterSystems, Veradigm, Medical Information Technology, and More
Black Book ranks Veradigm Payer Analytics the #1 Overall Payer Analytics Solutions Vendor in 2024
The Portnoy Law Firm Announces Investigation of Veradigm Inc. (OTCMKTS: MDRX)
Robbins LLP Reminds MDRX Stockholders it is Investigating the Officers and Directors of Veradigm Inc. to Determine if They Breached Fiduciary Duties Owed to Shareholders
Source: https://incomestatements.info
Category: Stock Reports